EuroPCR 2022 | Renal denervation increases long-term time in target blood pressure range compared with sham control

Most hypertensive patients do not reach target blood pressure level ranges despite optimal medical treatment. Regardless anti-hypertensive medication, patients undergoing radiofrequency renal denervation have seen significant improved control of blood pressure, with relevant clinical impact.

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

One of the outcomes we look at in chronic diseases such as hypertension and diabetes is time in target range (TTR) looking at how much time patients spend within a target BP range. In the context of hypertension, TTR has been shown to be an independent predictor of cardiovascular event reduction. 

This study looked at 3-year outcomes of the randomized sham controlled SPYRAL HTN-ON MED assessing TTR (target blood pressure at office/ambulatory 140mmHg) in patients receiving renal denervation vs. sham control. 

80 patients were randomized, mean age 53.9, mostly men (87%) with average 24hr systolic blood pressure 152 ±7 mmHg, with 93% adherence to medication in the SHAM group.

Prior studies had shown that patients with renal denervation had seen significant reduction of target blood pressure within 24 hrs. (Δ -10.0 mmHg, P=0.04). This study showed higher TTR for both office and ambulatory blood pressures (<140mmHg) at study kickoff and later at 6, 12, 24 and 36 month followup (non-significantly). 

Read also: EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

When looking at hypertension measurements, there was lower severe hypertension (≥180mmHg) in the renal denervation branch (3% vs 8.8%). When combining office 140 and ambulatory BPs 130 mmHg, TTR accuracy improved significantly. 

Conclusions

Patients undergoing renal denervation presented significantly higher TTR. We should look at the clinical implications of higher TTR with renal denervation, which helps reduce cardiovascular events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Renal Denervation Increases Long-term Time in Target Blood Pressure Range Compared with Sham Control (SPYRAL-HTN on-meds).

Source: Presented by Kandzari, D. E. en EuroPCR 2022, París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...